Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-05
2006-12-05
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S453000
Reexamination Certificate
active
07144914
ABSTRACT:
There is provided compounds of formula (I) wherein R1to R4, Rato Rf, A and B have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
REFERENCES:
patent: 3962449 (1976-06-01), Binning et al.
patent: 4459301 (1984-07-01), Binnig et al.
patent: 4550112 (1985-10-01), Schoen et al.
patent: 4556662 (1985-12-01), Binnig et al.
patent: 5468858 (1995-11-01), Berlin et al.
patent: 6107321 (2000-08-01), Madin
patent: 6355641 (2002-03-01), Coffen et al.
patent: 39 30 266 (1991-03-01), None
patent: 0 306 871 (1989-03-01), None
patent: 0 308 843 (1989-03-01), None
patent: 0 665 228 (1995-08-01), None
patent: 0 728 758 (1996-08-01), None
patent: WO-91/07405 (1991-05-01), None
patent: WO-95/13279 (1995-05-01), None
patent: WO-95/15327 (1995-06-01), None
patent: WO-96/07656 (1996-03-01), None
patent: WO-96/35691 (1996-11-01), None
patent: WO-97/10223 (1997-03-01), None
patent: WO-97/11945 (1997-04-01), None
patent: WO-98/06725 (1998-02-01), None
patent: WO-99/31100 (1999-06-01), None
patent: WO 01/04107 (2001-01-01), None
patent: WO-01/04107 (2001-01-01), None
Coffen et al, STN International, CAPLUS Database, Columbus, OH, Accession No. 2000:666717, Reg. No. 295341-40-1 (2005).
Stolle et al, STN International, HCAPLUS Database, Columbus, OH, Accession No., 2001:50635, Reg. No. 321129-97-9 (2006).
Obst, U., et al., “Synthesis of Novel Nonpeptidic Thrombin Inhibitors,” Helvetica Chimica Acta, vol. 83, 855-909 (2000).
Marko, I.E., et al., “Asymmetric Grignard Addition to Aldehydes. An Example of Inverse Temperature Dependence of Enantiomeric Excess,” Tetrahedron Asymmetry, vol. 5 (4), 569-572 (1994).
Obst. U., et al., “Molecular recognition at the thrombin active site: structure-based design and synthesis of potent and selective thrombin inhibitors and the X-ray crystal structures of two thrombin-inhibitor complexes,” Chemistry & Biology, vol. 4 (4), 287-295 (1997).
Obst, U., et al., “Design of Novel, Nonpeptidic Thrombin Inhibitors and Structure of a Thrombin—Inhibitor Complex,” Angew. Chem. Int. Ed. Engl., vol. 34 (16), 1739-1742 (1995).
“Special Report—Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression After Myocardial Infarction,” New England Journal of Medicine, vol. 321 (6), 406-412 (1989).
Garrison, G.L., et al., “Novel 3,7-Diheterabicyclo[3.3.1]nonanes That Possess Predominant Class III Antiarrhythmic Activity in 1-4 Day Post Infarction Dog Models: X-ray Diffraction Analysis of 3-[4-(1H-Imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nonane Dihydroperchlorate,” J. Med. Chem., vol. 39, 2559-2570 (1996).
Paroczai, M., et al., “Investigations to Characterize a New Antiarrhythmic Drug Bisaramil,” Pharmacol. Res., vol. 24 (2), 149-162 (1991).
Wang, J., et al., “Class III Antiarrhythmic Drug Action in Experiemental Atrial Fibrillation, Differences in Reverse Use Dependence and Effectiveness Between d-Sotalol and the New Antiarrhythmic Drug Ambasilide,” Circulation, vol. 90 (4), 2032-2040 (1994).
Chen, C.L., et al., “High-Performance Liquid Chromatographic Determination of SAZ-VII-22, a Novel Antiarrhythmic Agent, in Dog Plasma and Urine,” Analytical Sciences, vol. 9, 429-431 (1993).
Abou-Gharbia, M., et al., “Synthesis and Structure-Activity Relationship of Substituted Tetrahydro- and Hexahydro-1,2-benzisothiazol-3-one 1,1-Dioxides and Thiadiazinones: Potential Anxiolytic Agents,” J. Med. Chem., vol. 32, 1024-1033 (1989).
Ohnmacht, C.J., et al., “Synthesis and Carbon-13 NMR Study of 2-Benzyl, 2-Methyl, 2-Aryloctahydropyrrolo[3,4-c]pyrroles and the 1,2,3,5-Tetrahydropyrrolo[3,4-c]pyrrole Ring System,” J. Heterocyclic Chem., vol. 20, 321-329 (1983).
Knowles, P., et al., “A Synthesis of 3,7,10-Triazatricyclo [3.3.3.01.5]undecane, ‘3,7,10-Triaza[3.3.3]propellane’, and some Derivatives,” J. Chem. Soc. Perkin Trans. I, 1475-1477 (1983).
Altman, J., et al., “Propellanes-I Tricyclic Compounds Conjoined in a Carbon-Carbon Single Bond,” Tetrahedron, Suppl. 8, Part I, 279-304 (1966).
Dave, P.R., et al., “Facile Preparation of 3,7-Diazabicyclo[3.3.0]octane and 3,7,10-Triheterocyclic [3.3.3]Propellane Ring Systems from 1,5-Diazacyclooctane 3,7-Derivatives,” J. Org. Chem., vol. 61 (25), 8897-8903 (1996).
Padwa, A., et al., “Diastereofacial Selectivity in Azomethine Ylide Cycloaddition Reactions Derived from Chiral a-Cyanoaminosilanes,” Tetrahedron, vol. 41 (17), 3529-3535 (1985).
Axenborg, J.E., et al., “A PC-based on-line system for physiological in vivo and in vitro experiments,” Comput. Methods Programs Biomed., vol. 41, 55-67 (1993).
Weinges, K., et al., “Synthesen von 3.7-Dihetero-bicyclo[3.3.0]octanen,” Chem. Ber., vol. 101, 3010-3017 (1968).
Björsne Magnus
Pontén Fritiof
Strandlund Gert
Svensson Peder
Wilstermann Michael
Astrazeneca AB
Cozen O'Connor P.C.
Freistein Andrew B.
Jonsson Anneli
McKane Joseph K.
LandOfFree
3,7-diazabicyclo[3.3.0]octanes and their use in the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3,7-diazabicyclo[3.3.0]octanes and their use in the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3,7-diazabicyclo[3.3.0]octanes and their use in the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3718914